# Anthony P West

## List of Publications by Year in descending order



| | | | |
|---|---|---|---|
| 45 papers | 10,374 citations | 101384 36 h-index | 223531 46 g-index |
| 55 all docs | 55 docs citations | 55 times ranked | 13865 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 2020, 584, 437-442. | 13.7 | 1,742 |
| 2 | SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature, 2020, 588, 682-687. | 13.7 | 1,346 |
| 3 | Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell, 2020, 182, 828-842.e16. | 13.5 | 724 |
| 4 | Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature, 2015, 522, 487-491. | 13.7 | 665 |
| 5 | Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nature Medicine, 2017, 23, 185-191. | 15.2 | 399 |
| 6 | Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature, 2018, 561, 479-484. | 13.7 | 392 |
| 7 | Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design. Science, 2011, 334, 1289-1293. | 6.0 | 345 |
| 8 | Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy. Cell, 2014, 156, 633-648. | 13.5 | 318 |
| 9 | Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell, 2015, 161, 1280-1292. | 13.5 | 305 |
| 10 | Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science, 2021, 371, 735-741. | 6.0 | 305 |
| 11 | Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. Cell, 2017, 169, 597-609.e11. | 13.5 | 279 |
| 12 | Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. Journal of Experimental Medicine, 2013, 210, 655-663. | 4.2 | 275 |
| 13 | HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science, 2016, 352, 997-1001. | 6.0 | 263 |
| 14 | Crystal Structure and Immunoglobulin G Binding Properties of the Human Major Histocompatibility Complex-Related Fc Receptor,. Biochemistry, 2000, 39, 9698-9708. | 1.2 | 233 |
| 15 | Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2083-90. | 3.3 | 212 |
| 16 | Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike. Cell Reports, 2014, 7, 785-795. | 2.9 | 199 |
| 17 | Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nature Structural and Molecular Biology, 2016, 23, 906-915. | 3.6 | 188 |
| 18 | Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7385-7390. | 3.3 | 146 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature, 2019, 570, 468-473. | 13.7 | 145 |
| 20 | Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Science Translational Medicine, 2017, 9, . | 5.8 | 128 |
| 21 | The Chicken Yolk Sac IgY Receptor, a Functional Equivalent of the Mammalian MHC-Related Fc Receptor, Is a Phospholipase A2 Receptor Homolog. Immunity, 2004, 20, 601-610. | 6.6 | 126 |
| 22 | Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science, 2022, 377, . | 6.0 | 120 |
| 23 | Intra-Spike Crosslinking Overcomes Antibody Evasion by HIV-1. Cell, 2015, 160, 433-446. | 13.5 | 109 |
| 24 | Computational analysis of antiâ€“HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10598-10603. | 3.3 | 106 |
| 25 | Restricting HIV-1 pathways for escape using rationally designed antiâ€“HIV-1 antibodies. Journal of Experimental Medicine, 2013, 210, 1235-1249. | 4.2 | 85 |
| 26 | Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. Nature Communications, 2018, 9, 1251. | 5.8 | 85 |
| 27 | Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity, 2019, 50, 1513-1529.e9. | 6.6 | 85 |
| 28 | Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Reports, 2021, 36, 109760. | 2.9 | 80 |
| 29 | Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. Journal of Experimental Medicine, 2014, 211, 2361-2372. | 4.2 | 79 |
| 30 | B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell, 2021, 184, 3205-3221.e24. | 13.5 | 73 |
| 31 | Structural basis for germline antibody recognition of HIV-1 immunogens. ELife, 2016, 5, . | 2.8 | 68 |
| 32 | Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. Nature Communications, 2021, 12, 4886. | 5.8 | 65 |
| 33 | Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. ELife, 2017, 6, . | 2.8 | 52 |
| 34 | Design and Expression of a Dimeric Form of Human Immunodeficiency Virus Type 1 Antibody 2G12 with Increased Neutralization Potency. Journal of Virology, 2009, 83, 98-104. | 1.5 | 49 |
| 35 | Antibody engineering for increased potency, breadth and half-life. Current Opinion in HIV and AIDS, 2015, 10, 151-159. | 1.5 | 46 |
| 36 | Electron tomography visualization of HIV-1 fusion with target cells using fusion inhibitors to trap the pre-hairpin intermediate. ELife, 2020, 9, . | 2.8 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Structural Basis for Enhanced HIV-1 Neutralization by a Dimeric Immunoglobulin G Form of the Glycan-Recognizing Antibody 2G12. Cell Reports, 2013, 5, 1443-1455. | 2.9 | 36 |
| 38 | Evaluation of CD4-CD4i Antibody Architectures Yields Potent, Broadly Cross-Reactive Anti-Human Immunodeficiency Virus Reagents. Journal of Virology, 2010, 84, 261-269. | 1.5 | 34 |
| 39 | Anti-PolyQ Antibodies Recognize a Short PolyQ Stretch in Both Normal and Mutant Huntingtin Exon 1. Journal of Molecular Biology, 2015, 427, 2507-2519. | 2.0 | 31 |
| 40 | Single-Chain Fv-Based Anti-HIV Proteins: Potential and Limitations. Journal of Virology, 2012, 86, 195-202. | 1.5 | 29 |
| 41 | Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Science Translational Medicine, 2021, 13, eabk1533. | 5.8 | 27 |
| 42 | Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas. MBio, 2015, 6, . | 1.8 | 25 |
| 43 | Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. Journal of Experimental Medicine, 2021, 218, . | 4.2 | 25 |
| 44 | Structure of an HIV-2 gp120 in Complex with CD4. Journal of Virology, 2016, 90, 2112-2118. | 1.5 | 19 |
| 45 | A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. ELife, 2020, 9, . | 2.8 | 10 |